X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used for the development of DMT-310, a novel once-weekly topical treatment, currently in Phase II for patients with moderate-to-severe acne vulgaris.
Lead Product(s): DMT310
Therapeutic Area: Dermatology Product Name: DMT-310
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 16, 2023
Details:
DMT310 is a novel, once-weekly, topical product candidate derived from a freshwater sponge being developed for the treatment of multiple skin diseases like Acne Vulgaris.
Lead Product(s): DMT310,Hydrogen Peroxide
Therapeutic Area: Dermatology Product Name: DMT310
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
DMT310 is a novel, once-weekly, topical product and developed from Spongilla platform technology, which being investigated for the treatment of moderate-to-severe Acne.
Lead Product(s): DMT310
Therapeutic Area: Dermatology Product Name: DMT-310
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge, studied for the treatment of psoriasis and rosacea.
Lead Product(s): DMT310
Therapeutic Area: Dermatology Product Name: DMT-310
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
The Company intends to use the net proceeds for the development of DMT-310, a natural source of spongilla lacustris with multiple active components to treat inflammatory skin diseases including acne, psoriasis and rosacea.
Lead Product(s): DMT310
Therapeutic Area: Dermatology Product Name: DMT-310
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 20, 2023
Details:
DMT310 is a multifactorial natural product candidate derived from Spongilla lacustris, a unique freshwater sponge that is harvested under specific environmental conditions and then processed into a powder.
Lead Product(s): DMT310
Therapeutic Area: Dermatology Product Name: DMT310
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
DMT310 is the lead product, developed from Spongilla platform technology. The unique product candidate is derived from a natural source of Spongilla lacustris, which contains multiple active components to treat a variety of inflammatory skin diseases with weekly applications.
Lead Product(s): DMT310
Therapeutic Area: Dermatology Product Name: DMT310
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2022
Details:
In terms of safety and tolerability, DMT410 was generally safe and well tolerated with no adverse events reported, no withdrawals due to treatment-related adverse events, and no potential distant spread of toxin reported.
Lead Product(s): OnabotulinumtoxinA
Therapeutic Area: Dermatology Product Name: DMT410
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2021
Details:
DMT310 demonstrated a 19.6% reduction from baseline in pruritus at Week 8 this result supports further investigation of DMT310 in psoriasis for the treatment of moderate to severe acne, mild to moderate psoriasis and moderate to severe papulopustular rosacea.
Lead Product(s): DMT310
Therapeutic Area: Dermatology Product Name: DMT310
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
The Company intends to use substantially all of the net proceeds from the offering to advance the clinical development of DMT310 for the treatment of rosacea and psoriasis.
Lead Product(s): DMT310
Therapeutic Area: Dermatology Product Name: DMT310
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maxim Group LLC
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
